scholarly journals Fatal Tumor Thrombosis Due to an Inferior Vena Cava Leiomyosarcoma in a Patient With Antiphospholipid Antibody Syndrome

2002 ◽  
Vol 77 (6) ◽  
pp. 595-599 ◽  
Author(s):  
Joseph D. Espiritu ◽  
Michael H. Creer ◽  
Andrew Z. Miklos ◽  
Madhu S. Bajaj
Keyword(s):  
Inferior Vena Cava ◽  
Inferior Vena ◽  
Vena Cava ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Tumor Thrombosis

scholarly journals Antiphospholipid Antibody Syndrome Associated with Graves' Disease Presenting as Inferior Vena Cava Thrombosis with Bilateral Lower Limb DVT

2014 ◽  
Vol 7 ◽  
pp. CCRep.S15302 ◽  
Author(s):  
Ankur Jain
Keyword(s):  
Inferior Vena Cava ◽  
Lower Limb ◽  
Inferior Vena ◽  
Case Reports ◽  
Vena Cava ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Bilateral Lower Limb

We report a case of a 60-year-old lady who presented with bilateral lower limb swelling and a thyroid swelling with clinical features consistent with thyrotoxicosis. Investigations revealed the presence of a thrombus in bilateral external, internal iliac veins, and inferior vena cava extending up to its infrahepatic part. Hormone profile and radioiodine uptake scan confirmed the diagnosis of Graves' disease. Further workup revealed the presence of antiphospholipid antibodies (confirmed after a repeat test at 12 weeks). The patient was treated with antithyroid drugs and anticoagulants. The patient improved with normalization of thyroid function and partial recanalization of the infrahepatic part of inferior vena cava. Hyperthyroidism has been implicated as a potential hypercoagulable state; however, the association of Graves' disease with antiphospholipid antibody syndrome is limited to isolated case reports. This case highlights a new mechanism underlying hypercoagulability associated with Graves' disease.

scholarly journals Thrombotic storm in a 4-year-old boy with a thrombus in the right atrium

2018 ◽  
Vol 32 ◽  
pp. 205873841877812 ◽  
Author(s):  
Jing-Yao Ma ◽  
Xin Zhang ◽  
Xiao-Feng Li ◽  
Le-Jian He ◽  
Ning Ma ◽  
...  
Keyword(s):  
Inferior Vena Cava ◽  
Anticoagulant Therapy ◽  
Right Atrium ◽  
Inferior Vena ◽  
Vena Cava ◽  
Pathological Examination ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Tumor Embolus ◽  
Embolism And Thrombosis

Thrombotic storm (TS) is a rare disease, especially with thrombus in the heart of pediatric patient. We present a case of a 4-year-old boy, who was diagnosed with TS during his first hospitalization due to lower extremity deep venous thrombosis, pulmonary embolism, and thrombosis of the inferior vena cava, cerebral, left internal jugular, portal, renal, and iliac veins. He was eventually prescribed with rivaroxaban to control thrombosis after 30 days of successive use of low-molecular-weight heparin, unfractionated heparin, and warfarin, which were demonstrating little effect on preventing thrombosis, and the patient was intolerant to argatroban. While his lupus anticoagulant ratio was slightly above the normal range and no other potential causes such as congenital thrombophilia, severe infection, malignancy, and trauma were confirmed, we suspected antiphospholipid antibody syndrome and prescribed glucocorticoid and rituximab to control the disease. After 36 days of admission, ultrasonography showed recanalization of the former thrombus. One month after discharge, a tumor embolus resembling a mass emerged in his right atrium under effective anticoagulant therapy. During his second admission, he underwent surgical thrombectomy, and pathological examination confirmed the mass to be a platelet-rich thrombus rather than tumor embolus or infection. Considering the suspected antiphospholipid antibody syndrome as the cause of the TS, we prescribed aspirin combined with rivaroxaban to prevent thrombosis. In this case, surgery and pathology shed light on the type of thrombus that emerged from the inferior vena cava and traveled to the heart, which is the possible potential cause of TS. It also changed our therapeutic strategy to antiplatelet therapy combined with anticoagulant therapy to control the disease.

Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava

2015 ◽  
pp. 68
Author(s):  
A. V. Vishnevskiĭ ◽  
O. I. Andreĭtseva ◽  
A. F. Kharazov ◽  
A. Iu. Gritsiuta ◽  
D. V. Kalinin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inferior Vena Cava ◽  
Inferior Vena ◽  
Vena Cava ◽  
Tumor Thrombosis

scholarly journals Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy

2016 ◽  
Vol 57 (5) ◽  
pp. 512-523 ◽  
Author(s):  
Yoshiro Matsuo ◽  
Kenji Yoshida ◽  
Hideki Nishimura ◽  
Yasuo Ejima ◽  
Daisuke Miyawaki ◽  
...  
Keyword(s):  
Inferior Vena Cava ◽  
Portal Vein ◽  
Stereotactic Body Radiotherapy ◽  
Inferior Vena ◽  
Three Dimensional ◽  
Vena Cava ◽  
Conformal Radiotherapy ◽  
Portal Vein Tumor Thrombosis ◽  
Tumor Thrombosis ◽  
Three Dimensional Conformal Radiotherapy

Abstract This study aimed to evaluate the efficacy of stereotactic body radiotherapy (SBRT) compared with three-dimensional conformal radiotherapy (3DCRT). Forty-three patients with portal vein tumor thrombosis (PVTT)/inferior vena cava tumor thrombosis (IVCTT) treated with SBRT (27 with CyberKnife (CK) and 16 with TrueBeam (TB)) from April 2013 to December 2014, and 54 treated with 3DCRT from June 2008 to March 2013 were evaluated. Dosimetric parameters, response to radiotherapy (RT) and survival outcomes were compared in total SBRT vs. 3DCRT, CK vs. 3DCRT and TB vs. 3DCRT, respectively. The median biologically effective dose 10 (BED10) values in total SBRT, CK, TB and 3DCRT were 73.4 Gy10, 75.0 Gy10, 60.5 Gy10 and 58.5 Gy10, respectively (P < 0.001 in total SBRT vs. 3DCRT, P < 0.001 in CK vs. 3DCRT, P = 0.004 in TB vs. 3DCRT). The tumor response rates were 67%, 70%, 62% and 46%, respectively (P = 0.04, P = 0.04, P = 0.25). The 1-year overall survival rates were 49.3%, 56.7%, 38.1% and 29.3%, respectively (P = 0.02, P = 0.02, P = 0.30), and the 1-year local progression rates were 20.4%, 21.9%, 18.8% and 43.6%, respectively (P = 0.01, P = 0.04, P = 0.10). The use of SBRT made it possible to achieve a higher BED10 compared with the use of 3DCRT. Improvements in local control and survival were achieved in the CK group and the total SBRT group. Our results suggest that SBRT may have the potential to be the standard RT technique for the treatment of PVTT/IVCTT.

Sign in / Sign up

Export Citation Format

Share Document